A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Wu, Pei Fang ^a   Lin, Ching Hung ^a   Kuo, Ching Hua ^b   Chen, Wei Wu ^a   Yeh, Dah Cherng ^c   Liao, Hsiao Wei ^b   Huang, Shu Min ^a   Cheng, Ann Lii ^a,b   Lu, Yen Shen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Anti angiogenic therapy; Anti VEGF therapy; Bevacizumab; Leptomeningeal carcinomatosis; Vascular endothelial growth factor (VEGF)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CISPLATIN; ETOPOSIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; INHIBITION KINETICS; LEUKOPENIA; LYMPHOCYTE COUNT; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; THROMBOCYTE COUNT; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; ANIMAL; BREAST NEOPLASMS; CANCER STAGING; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMPLICATION; FEMALE; MENINGEAL CARCINOMATOSIS; MOUSE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; MENINGEAL CARCINOMATOSIS; MICE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84928008142     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1290-1     Document Type: Article

References (31)

1. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11(9):871-9.
2. Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16(8):1175-88.
3. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer. 2004;91(2):219-24.
4. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2005;65(7):1120-2.
5. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009;94(2):229-34.
6. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest. 2003;33(1):76-81.
7. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, et al. Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clin Cancer Res. 2015; 21(8):1851-8. doi: 10.1158/1078-0432.CCR-14-2075. Epub 2015 Feb 19.
8. Liao HW LY, Lin CH, Kuo CH. A rapid and sensitive liquid chromatography tandem mass spectrometry method for quantification of etoposide and etoposide chatechol in cerebrospinal fluid (PMo-003). In: International Mass Spectrometry Conference 2012. 2012.
9. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-9.
10. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008;10(2):208-15.
11. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-402.
12. Shigekawa T, Takeuchi H, Misumi M, Matsuura K, Sano H, Fujiuchi N, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer. 2009;16(1):88-92.
13. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85(2):223-7.
14. Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer. 2006;7(2):164-6.
15. Paydas S, Bicakci K, Yavuz S. Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med. 2009;20(1):96-9.
16. Ku GY, Krol G, Ilson DH. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol. 2007;25(13):e14-6.
17. Onishi H, Morisaki T, Nakafusa Y, Nakashima Y, Yokohata K, Katano M. Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol. 2011;16(6):718-21.
18. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348-54.
19. Tetef ML, Margolin KA, Doroshow JH, Akman S, Leong LA, Morgan Jr RJ, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46(1):19-26.
20. Kiewe P, Thiel E, Reinwald M, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neurooncol. 2011;103(3):629-34.
21. Peereboom DM, Murphy C, Ahluwalia MS, Conlin A, Eichler A, Van Poznak C, et al. Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro Oncol. 2014;16(4):579-83.
22. Segura PP, Gil M, Balana C, Chacon I, Langa JM, Martin M, et al. Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. J Neurooncol. 2012;109(1):137-42.
23. Groves MD, DeGroot J, Tremont I, Forman A, Kang S, Pei BL, et al. A pilot study of systemically administered bevacizumab in patients with neoplastic meningitis: imaging, clinical, CSF, and biomarker outcomes. Neuro Oncol (2011). 2011;13 suppl 3:iii85-91.
24. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996;77(7):1315-23.
25. Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol. 2007;84(1):57-62.
26. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11(3):561-9.
27. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
29. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13(13):3942-50.
30. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012;21(1):82-91.
31. Lu YS CB, Lin CH, Chen WW, Wu PF, Cheng AL, Shih Tiffany TF. Normalization of tumor vasculature by anti-angiogenesis therapy in metastatic tumor: A clinical study to determine the timing and effect. Proceedings: AACR Annual Meeting 2014. Cancer Res. 2014;74:abstract 2984.